manufactured · input
Sterile multilayer polyethylene (LLDPE + EVOH) bags used in wave and stirred-tank bioreactors for cell culture. Cytiva and Sartorius dominate ~70–80% of market. The polyethylene film itself — not the finished bag — was the limiting bottleneck in 2020–2021.
4
Source countries
9
Companies
1
Goods affected
0
Claims on record
What depends on it
1 essential American goods rely on single-use bioreactor bags (cellbag) somewhere upstream in their supply chain.
Where it comes from
Share of global supply, by country.
| Country | Share of supply |
|---|---|
| USUnited States | 37% |
| DEGermany | 30% |
| SESweden | 20% |
| FRFrance | 8% |
Who makes it
9 companies produce single-use bioreactor bags (cellbag).
German life sciences company that manufactured the world's first industrial nitrocellulose membrane in 1960 in Göttingen. Its Unisart® CN series is one of the two dominant global LFA membrane brands. Key OEM supplier to virtually every major rapid test manufacturer.
Second-largest single-use bioreactor bag producer; ~25–30% global market share. Revenue ~€3.5B (2024). Produces Biostat STR and Ambr bioreactor systems with proprietary bag technology. Manufacturing in Goettingen (Germany) and Aubagne (France). A publicly traded subsidiary of Sartorius AG. Sartorius Stedim expanded bioreactor bag capacity significantly during COVID-19 and has been the fastest-growing supplier since. Also manufactures filtration membranes and chromatography media for the same biopharma customers.
World's largest single-use bioreactor bag manufacturer; ~40–45% global market share. Spun out from GE Healthcare and acquired by Danaher Corporation in 2020 ($21.4B). Revenue ~$4B (2024). Produces WAVE Cellbag™ bioreactor bags (10 mL to 1,000 L) used in mAb, vaccine, and cell therapy production. Cytiva's Cellbag was the primary bottleneck limiting COVID-19 vaccine production speed in 2020–21. Manufacturing at Logan, UT (US), Umeå (Sweden), and Whatman, Maidstone (UK).
Washington DC-based conglomerate that owns Cytiva (Whatman brand — nitrocellulose membranes, glass fiber pads), IDT (oligonucleotide probes), and Pall Corporation (filtration). Controls an extraordinary concentration of IVD supply chain chokepoints through acquisitions across multiple independent critical nodes.
Major bioreactor bag producer via HyPerforma single-use bioreactor (SUB) product line. ~15% global market share. Revenue ~$43B total (2024); bioprocessing segment ~$6B. Manufactures HyPerforma bags at Logan, UT and multiple international sites. Thermo Fisher also manufactures the LLDPE/EVOH film that goes into its own bags and sells to some competitors. Acquired PAA Laboratories and Gibco brands which supply the same customers.
German science and technology company (Darmstadt; family-owned since 1668; €22B revenue); life science division (MilliporeSigma in US/Canada, Millipore globally) is the world's leading producer of pharmaceutical sterilizing-grade membrane filters under the Durapore® (PVDF), Millipak®, and Express® SHC brands. Durapore 0.22 μm PVDF filters are the industry benchmark for IV fluid sterilizing filtration — validated by virtually every major IV fluid manufacturer globally. Merck KGaA has been family-controlled since 1668 — making it the world's oldest operating pharmaceutical company (predating most European nations in their current form). The Merck family still controls >70% of shares through their foundation. The same 350-year-old German family company that supplied dyes to the First World War German army now makes the sterilizing filters that make every IV bag sterile. Note: US Merck (MSD/Merck & Co.) is a separate company that split from Merck KGaA after World War I when its US subsidiary was seized as enemy property and sold.
World's largest vaccine manufacturer by dose volume — ~1.9–2.0 billion doses/year as of 2023, representing ~60% of global vaccine production. Produces routine childhood vaccines (polio, measles, DTP, BCG), COVID vaccines, and others for Gavi-eligible markets. Single-site concentration risk in Pune.
